Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

401003 (±)-Ibuprofen - CAS 15687-27-1 - Calbiochem

A nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible and competitive inhibitor of cyclooxygenase 1 (COX-1) (IC₅₀ = 4.85 µM).

(±)-Ibuprofen - CAS 15687-27-1 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: [(±)-2-(4-Isobutylphenyl)-propionic Acid

Primary Target: COX-1
401003
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
15687-27-1C₁₃H₁₈O₂

Products

RéférenceConditionnement Qté
401003-1GM Ampoule plast. 1 gm
Description
OverviewA nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible and competitive inhibitor of cyclooxygenase 1 (COX-1) (IC50 = 4.85 µM). Inhibits COX-2 at higher concentrations (IC50 = 223 µM). Blocks aspirin inactivation of COX-1 (EC50 antagonism of 200 µM aspirin = 290 nM). Shown to reduce the total Aβ secretion (Amyloid β40 and 42) in human neuronal cells and offers neuroprotection against glutamate-, nitric oxide-, and superoxide-induced damage. Reported to activate peroxisome proliferator-activated receptors (PPAR) α and γ in both CV-1 and C3H10T1/2 cells (~100 µM-500 µM).
Catalogue Number401003
Brand Family Calbiochem®
Synonyms[(±)-2-(4-Isobutylphenyl)-propionic Acid
References
ReferencesAsanuma, M., et al. 2001. J. Neurochem. 76, 1895.
Blasko, I., et al. 2001. Neurobiol. Dis. 8, 1094.
Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA 98, 14583.
Casper, D., et al. 2000. Neurosci. Lett. 289, 201.
Lambat, Z., et al. 2000. Metab. Brain Dis. 15, 249.
Lim, G.P., et al. 2000. J. Neurosci. 20, 5709.
Ogawa, O., et al. 2000. Eur. J. Pharmacol. 408, 137.
Wyss-Coray, T., and Mucke, L. 2000. Nat. Med. 6, 973.
Lehmann, J.M., et al. 1997. J. Biol. Chem. 272, 3406.
Boneburg, E.M., et al. 1996. J. Clin. Pharmacol. 36, 16S.
Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA 90, 11693.
Product Information
CAS number15687-27-1
ATP CompetitiveY
FormWhite solid
Hill FormulaC₁₃H₁₈O₂
Chemical formulaC₁₃H₁₈O₂
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetCOX-1
Primary Target IC<sub>50</sub>4.85 µM against COX-1
Purity≥98% by titration
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSMU6640000
Safety Information
R PhraseR: 22

Harmful if swallowed.
S PhraseS: 36

Wear suitable protective clothing.
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful
Storage +15°C to +30°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
401003-1GM 04055977189377

Documentation

(±)-Ibuprofen - CAS 15687-27-1 - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

(±)-Ibuprofen - CAS 15687-27-1 - Calbiochem Certificats d'analyse

TitreNuméro de lot
401003

Références bibliographiques

Aperçu de la référence bibliographique
Asanuma, M., et al. 2001. J. Neurochem. 76, 1895.
Blasko, I., et al. 2001. Neurobiol. Dis. 8, 1094.
Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA 98, 14583.
Casper, D., et al. 2000. Neurosci. Lett. 289, 201.
Lambat, Z., et al. 2000. Metab. Brain Dis. 15, 249.
Lim, G.P., et al. 2000. J. Neurosci. 20, 5709.
Ogawa, O., et al. 2000. Eur. J. Pharmacol. 408, 137.
Wyss-Coray, T., and Mucke, L. 2000. Nat. Med. 6, 973.
Lehmann, J.M., et al. 1997. J. Biol. Chem. 272, 3406.
Boneburg, E.M., et al. 1996. J. Clin. Pharmacol. 36, 16S.
Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA 90, 11693.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision28-April-2008 JSW
Synonyms[(±)-2-(4-Isobutylphenyl)-propionic Acid
DescriptionA nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible, competitive, non-selective cyclooxygenase (COX) inhibitor (IC50 = 4.85 µM for purified COX-1 and 223 µM for purified COX-2). Also reported to inhibit COX-1 and COX-2 activity in intact bovine aortic endothelial cells (BAEC) (IC50 = 7 µM for COX-1 and 72.7 µM for COX-2). Potently blocks aspirin inactivation of COX-1 (EC50 antagonism of 200 µM aspirin ~290 nM for ovine COX-1). Decreases the secretion of total Aβ (Amyloid β40&42) by human neuronal cells and offers neuroprotection against glutamate-, nitric oxide- and superoxide-induced damage. Activates peroxisome proliferator activated receptors α and γ in both CV-1 and C3H10T1/2 cells (~100 µM - 500 µM).
FormWhite solid
CAS number15687-27-1
RTECSMU6640000
Chemical formulaC₁₃H₁₈O₂
Structure formulaStructure formula
Purity≥98% by titration
SolubilityDMSO (5 mg/ml) or Ethanol (1 mg/ml)
Storage Protect from light
+15°C to +30°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Harmful
Merck USA index14, 4881
ReferencesAsanuma, M., et al. 2001. J. Neurochem. 76, 1895.
Blasko, I., et al. 2001. Neurobiol. Dis. 8, 1094.
Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA 98, 14583.
Casper, D., et al. 2000. Neurosci. Lett. 289, 201.
Lambat, Z., et al. 2000. Metab. Brain Dis. 15, 249.
Lim, G.P., et al. 2000. J. Neurosci. 20, 5709.
Ogawa, O., et al. 2000. Eur. J. Pharmacol. 408, 137.
Wyss-Coray, T., and Mucke, L. 2000. Nat. Med. 6, 973.
Lehmann, J.M., et al. 1997. J. Biol. Chem. 272, 3406.
Boneburg, E.M., et al. 1996. J. Clin. Pharmacol. 36, 16S.
Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA 90, 11693.